Treatment in Autoimmune Disease
Anokion is an innovative immune tolerance company focused on providing a more effective approach to treating autoimmune disease. Our proprietary immune tolerance platform features proteins, or antigens, that are engineered to deliver precise, targeted disease therapy, without the side effects of broad immunosuppression. Anokion’s antigen-specific platform can be translated to virtually any antigen-mediated disease, with widespread potential across multiple clinical applications.
- February 27, 2020
Anokion Announces Initiation of Patient Dosing in Phase 1 Clinical Trial of KAN-101 in Celiac Disease| Read More